These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33993526)

  • 21. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
    Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Harrison S; MacDonald S; Lock K; Anis AH; Marsh DC; Schechter MT
    J Subst Abuse Treat; 2019 Jun; 101():50-54. PubMed ID: 31174713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.
    Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Nosyk B; Krausz M; Anis A; Schechter MT
    J Subst Abuse Treat; 2010 Jun; 38(4):408-11. PubMed ID: 20359843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series.
    Brar R; Fairbairn N; Colizza K; Ryan A; Nolan S
    J Addict Med; 2021 Apr; 15(2):163-166. PubMed ID: 32769776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Injectable Opioid Agonist Therapy in a In-Patient Setting for a Pregnant Patient With Opioid Use Disorder: A Case Report.
    Griffiths S; Campbell DM; Caudarella A; Guimond T; Lamba W; Lurie E; Nader M; Sgro M; Turner S
    J Addict Med; 2021 Sep-Oct 01; 15(5):435-438. PubMed ID: 33234803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs.
    Ohlendorf E; Perez-Correa A; Riback L; Ghiroli M; Lopez-Castro T; Fox AD
    J Addict Med; 2023 May-Jun 01; 17(3):e148-e155. PubMed ID: 37267166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing.
    Harris MT; Seliga RK; Fairbairn N; Nolan S; Walley AY; Weinstein ZM; Turnbull J
    Int J Drug Policy; 2021 Dec; 98():103400. PubMed ID: 34469781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths.
    Tse WC; Scott N; Dietze P; Nielsen S
    J Subst Abuse Treat; 2022 Dec; 143():108871. PubMed ID: 36182753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breastfeeding on Injectable Opioid Agonist Therapy: A Case Report.
    Patricelli CJ; Gouin IJ; Gordon S; Carter N; Albert A; Paquette V; Stewart K; George S; Urbanoski K
    J Addict Med; 2023 Mar-Apr 01; 17(2):222-226. PubMed ID: 36001061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach.
    Palis H; Guh D; MacDonald S; Harrison S; Brissette S; Marsh DC; Schechter MT; Oviedo-Joekes E
    Drug Alcohol Depend; 2021 Jan; 218():108333. PubMed ID: 33268225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA).
    Allen ST; Schneider KE; Rouhani S; White RH; Morris M; Owczarzak J; Sherman SG
    Ann Med; 2023 Dec; 55(1):2196435. PubMed ID: 37078710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of injectable opioid agonist treatment in hospital: A case report.
    McAdam M; Brar R; Young S
    Drug Alcohol Rev; 2020 Feb; 39(2):138-141. PubMed ID: 31814186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report.
    Palis H; MacDonald S; Jun J; Oviedo-Joekes E
    Harm Reduct J; 2021 May; 18(1):57. PubMed ID: 34016137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.
    Oviedo-Joekes E; Marsh DC; Guh D; Brissette S; Schechter MT
    J Opioid Manag; 2011; 7(5):371-6. PubMed ID: 22165036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV Treatment Initiation and Retention Among Individuals Initiated on Injectable Opioid Agonist Therapy for Severe Opioid Use Disorder: A Case Series.
    Giang V; Brar R; Sutherland C; Nolan S
    J Addict Med; 2020; 14(5):437-440. PubMed ID: 32011407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study.
    Ivsins A; Boyd J; Mayer S; Collins A; Sutherland C; Kerr T; McNeil R
    Drug Alcohol Depend; 2020 Nov; 216():108202. PubMed ID: 32948372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder.
    Brar R; Sutherland C; Nolan S
    BMJ Case Rep; 2019 Aug; 12(7):. PubMed ID: 31371332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "COVID just kind of opened a can of whoop-ass": The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada.
    Glegg S; McCrae K; Kolla G; Touesnard N; Turnbull J; Brothers TD; Brar R; Sutherland C; Le Foll B; Sereda A; Goyer MÈ; Rai N; Bernstein S; Fairbairn N
    Int J Drug Policy; 2022 Aug; 106():103742. PubMed ID: 35679695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eligibility for heroin-assisted treatment (HAT) among people who inject opioids and are living with HIV in a Canadian setting.
    Klimas J; Dong H; Fairbairn N; Socías E; Barrios R; Wood E; Kerr T; Montaner J; Milloy MJ
    Addict Sci Clin Pract; 2018 Feb; 13(1):3. PubMed ID: 29409539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Supervised Injectable Opioid Treatment for the Management of Opioid Dependence.
    Bell J; Belackova V; Lintzeris N
    Drugs; 2018 Sep; 78(13):1339-1352. PubMed ID: 30132259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.
    Friedmann Z; Kinkel HT; Kühner C; Zsolnai A; Mick I; Binder A
    Harm Reduct J; 2023 Nov; 20(1):162. PubMed ID: 37915058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.